https://www.facebook.com/171064186888575/

Antidote.me

Call Directions

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Antidote.me, Medical and health, 400 Madison Avenue, New York, NY.

09/29/2026

🫀 Heart disease trials still hinge on one hard problem:
𝗳𝗶𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀.

In one heart failure feasibility test, we found:
✅ Patients knew their general diagnosis
❌ Most couldn't confirm the specific subtype or threshold the trial needed

Interest was high.
It wasn’t the issue. 𝗦𝗲𝗹𝗳-𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝘄𝗮𝘀.

That's exactly what a 𝗺𝗮𝗿𝗸𝗲𝘁 𝗳𝗲𝗮𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗿𝗲𝗽𝗼𝗿𝘁 is for.

It shows sponsors:
👉 Where patient self-report can be trusted
👉 Where you need contact-center or clinical confirmation instead

So outreach isn't wasted on patients who'll self-exclude later

If your protocol leans on what patients can confirm about themselves,
Let’s check it out before it's locked:

📅 Book a pre-launch feasibility review: https://www.antidote.me/researchers/contact
🔗 See how feasibility testing works: https://www.antidote.me/sponsors

09/24/2026

𝗧𝗵𝗲 𝗹𝗶𝗺𝗶𝘁𝗶𝗻𝗴 𝗳𝗮𝗰𝘁𝗼𝗿 𝘄𝗮𝘀𝗻'𝘁 𝘁𝗵𝗲 𝗮𝘂𝗱𝗶𝗲𝗻𝗰𝗲. 𝗜𝘁 𝘄𝗮𝘀 𝘁𝗵𝗲 𝗽𝗿𝗼𝘁𝗼𝗰𝗼𝗹.
Out of 214 patients, only 9 qualified.

Finding the right patients is its own challenge.

In patient recruitment, low qualification
doesn't always mean low interest.

This newest article tells you why:
🔗https://link.msgsndr.com/sp/a4b795cfe30

09/21/2026

𝗢𝗻𝗹𝘆 𝟵 𝗼𝘂𝘁 𝗼𝗳 𝟮𝟭𝟰 𝗾𝘂𝗮𝗹𝗶𝗳𝗶𝗲𝗱. 𝗔𝗹𝗹 𝘀𝘁𝗶𝗹𝗹 𝘄𝗮𝗻𝘁𝗲𝗱 𝗶𝗻. 🤔💭

World Alzheimer's Day puts a spotlight on the brain, aging,
and the neurodegenerative research
that includes 🧠 Parkinson's disease.

Finding those patients is where most trials stall.
In patient recruitment,
low qualification doesn't always mean low interest.

𝗧𝗵𝗲 𝗙𝗲𝗮𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗧𝗲𝘀𝘁.
In a recent Parkinson's Market Feasibility Test,
214 people came forward and 9 qualified,
and 100% of them asked to be contacted
about a study near them.

𝗜𝗳 𝘆𝗼𝘂𝗿 𝗲𝗻𝗿𝗼𝗹𝗹𝗺𝗲𝗻𝘁 𝗻𝘂𝗺𝗯𝗲𝗿𝘀 𝗹𝗼𝗼𝗸 𝗹𝗼𝘄,
l𝗲𝘁'𝘀 𝗳𝗶𝗻𝗱 𝗼𝘂𝘁 𝘄𝗵𝘆 𝗯𝗲𝗳𝗼𝗿𝗲 𝘆𝗼𝘂 𝗮𝘀𝘀𝘂𝗺𝗲 𝗶𝘁'𝘀 𝗱𝗲𝗺𝗮𝗻𝗱:

📅 𝗕𝗼𝗼𝗸 𝗮 𝗿𝗲𝗰𝗿𝘂𝗶𝘁𝗺𝗲𝗻𝘁 𝘀𝗽𝗲𝗲𝗱 𝗮𝘂𝗱𝗶𝘁: https://www.antidote.me/researchers/contact
🔗 𝗦𝗲𝗲 𝗵𝗼𝘄 𝗳𝗲𝗮𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝘄𝗼𝗿𝗸𝘀: https://www.antidote.me/sponsors

09/18/2026

𝗛𝗼𝘄 𝘁𝗵𝗲 𝗦𝗹𝗲𝗲𝗽-𝗔𝗽𝗻𝗲𝗮 𝘁𝗲𝘀𝘁 𝗰𝗮𝗺𝗲 𝘁𝗼 𝗯𝗲 😴
Just a vacuum-cleaner blower, a mask, and a stubborn idea.

That’s how Dr. Colin Sullivan
built the first nasal CPAP machine in 1981
and changed sleep apnea care.

Forty years on, sleep apnea studies rarely stalls.
But they did so on eligibility.

In one OSA device-interest feasibility,
𝗼𝗻𝗲 𝗿𝘂𝗹𝗲 𝗳𝗶𝗹𝘁𝗲𝗿𝗲𝗱 𝟯𝟲.𝟴% 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 on BMI alone,
before anyone reached a clinical site.

A single threshold can shrink
a qualified pool faster than any awareness gap.

Is your protocol filtering out the patients you need?
We’ll find it out for you: https://www.antidote.me/researchers/contact

09/16/2026

𝗜𝗿𝗿𝗲𝗴𝘂𝗹𝗮𝗿 𝗛𝗲𝗮𝗿𝘁𝗯𝗲𝗮𝘁? 💗

Atrial fibrillation is one of the most common
heart rhythm conditions in the world.

It is also one of the quietest.
About 1 in 3 people who have it don't know they do
(American Heart Association).

That creates a challenge
many study teams underestimate.

You cannot enroll patients
who don't yet know they qualify.

The gap between '𝘄𝗲 𝘁𝗵𝗶𝗻𝗸 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗿𝗲 𝗼𝘂𝘁 𝘁𝗵𝗲𝗿𝗲' and
'𝘄𝗲 𝗸𝗻𝗼𝘄 𝗵𝗼𝘄 𝘁𝗼 𝗿𝗲𝗮𝗰𝗵 𝘁𝗵𝗲𝗺' is where trials lose months.

Let's close it — comment '𝗥𝗘𝗔𝗖𝗛' below and we'll follow up.

09/10/2026

The first clinical trial 📋

In 1747, a naval doctor named James Lind ran what many consider the first controlled clinical trial.

His patients were sailors dying of scurvy.
His method was simple: divide them into groups,
give each a different remedy, and see what actually worked.

The sailors given citrus recovered.
The rest did not.
It was one of the first times a
treatment was tested rather than assumed.

Nearly 300 years later, the principle still holds.
The most reliable way to know whether something
works is to test it against reality,
not to trust that it should.

The same is true long before a study opens.

A protocol can read perfectly on paper
and still struggle the moment it meets real patients.

The eligibility rules, the messaging, the assumptions about who will say yes, all of it holds up better when it has been tested first.
Lind tested before he trusted.

09/09/2026

National Childhood Obesity Awareness Month

September is National Childhood Obesity Awareness Month, and about 1 in 5 U.S. children now live with obesity (CDC).

But even when a condition is common, clinical trial recruitment can still be challenging. The reason isn't always lack of patient interest-it can be eligibility.

In one obesity medication-switch feasibility test, patient interest remained high, yet only about 3% of respondents met the study criteria once treatment-history and dose-stability requirements were applied.

That's the kind of recruitment risk that can stay hidden until a study is live and sites are already carrying the screening burden. A market feasibility test surfaces it earlier: it runs your draft eligibility criteria against real patients, then shows exactly where willing people fall out.

The result: Fewer surprises for your clinical sites.

A clearer read on whether a low qualified rate means weak demand or a narrow protocol.

08/02/2026

Adding trial sites cannot fix a problem that sits upstream of your site list.

In one Parkinson's market test, 4% of patients who came forward met the protocol's criteria, and 100% of those who qualified asked to join. More sites would have screened the same population to the same result.

Our latest brief shows how to confirm recruitment potential before you commit budget and timeline to a site network.

Download the brief: https://hubs.ly/Q04qTy5_0

07/27/2026

More clinical sites don’t mean more patient enrollment for your study.

Adding sites expands how many patients you can screen, not how many can qualify.

In one Parkinson's market test, 4% of patients who came forward met the protocol's eligibility criteria. Every added site would have screened the same population to the same result.

Our latest blog explains why site expansion fails as an enrollment rescue, and what to test before you build the network.

Read the blog here: https://hubs.ly/Q04qTlwY0

06/25/2026

Study teams don’t need more recruitment assumptions before launch.

They need real-world patient insight.

Before broader recruitment begins, a Market Feasibility Test helps sponsors understand whether the patient population is reachable, where qualification drops off, and which recruitment risks need attention first.

Antidote’s MFTs capture real patient response early, so sponsors can identify reach gaps, eligibility loss, and qualification potential before sites carry the burden.

Our latest blog explains how MFTs support stronger recruitment planning before study launch.

Read more here: https://hubs.ly/Q04m71qJ0

Address

400 Madison Avenue
New York, NY
10017

Telephone

(888)5091308

Website

facebook.com

Alerts

Be the first to know and let us send you an email when Antidote.me posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed health & beauty business in New York?